Clinical Trials Browser

bivatuzumab mertansine × Tumor-Agnostic × Clear all

NCT02254044 2014-10-01

Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus

Phase 1 Terminated

Carcinoma, Squamous Cell